Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells

International Journal of Cancer

Volumn 121, Issue 3, 2007, Pages 520-527

  Carey, Anne Marie ^a   Pramanik, Rashida ^a   Nicholson, Linda J ^b   Dew, Tracy K ^c   Martin, Francis L ^d   Muir, Gordon H ^c   Morris, Jonathan D H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Androgen; ERK; MEK; Prostate cancer; Ras; Refractory disease

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANDROGEN RECEPTOR; BICALUTAMIDE; LUCIFERASE; METRIBOLONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; RAS PROTEIN;

ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA DETERMINATION; DNA SYNTHESIS; GENE ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REPORTER GENE; SIGNAL TRANSDUCTION;

BUTADIENES; CELL PROLIFERATION; DNA, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MALE; METHIONINE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROSTATIC NEOPLASMS; RAS PROTEINS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 34250901788     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22715     Document Type: Article

References (45)

1. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor a in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545-50.
2. Gioeli D. Signal transduction in prostate cancer progression. Clin Sci (Lond) 2005;108:293-308.
3. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
4. Robinson D, He F, Pretlow T, Kung HJ. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 1996;93:5958-62.
5. Moore TM, Garg R, Johnson C, Coptcoat MJ, Ridley AJ, Morris JD. PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization. J Biol Chem 2000;275:4311-22.
6. Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez AC. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 1999;274:6935-45.
7. George DJ. Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. Urology 2002;60:115-21. discussion 22.
8. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. Response of prostate cancer to anti-Her-2/ neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 1999;59:4761-4.
9. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia. Prostate 1996;29:282-6.
10. Russell PJ, Bennett S, Strieker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-23.
11. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999;18:2755-61.
12. Byrne RL, Leung H, Neal DE. Peptide growth factors in the prostate as mediators of stromal epithelial interaction. Br J Urol 1996;77:627-33.
13. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003;162:655-63.
14. Tillotson JK, Rose DP. Endogenous secretion of epidermal growth factor peptides stimulates growth of DU145 prostate cancer cells. Cancer Lett 1991;60:109-12.
15. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
16. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
17. Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE. Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene. 1997;15:1115-20.
18. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-25.
19. Kumar VL, Majumder PK, Gujral S, Kumar V. Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate. Cancer Lett 1998;134: 177-80.
20. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999;41:275-80.
21. Watanabe M, Fukutome K, Kato H, Murata M, Kawamura J, Shiraishi T, Yatani R. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett 1999;141:173-8.
22. Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D, Resnick MI, Kursh ED, Pretlow TP, Pretlow TG. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 1998;90:519-23.
23. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, Ayala G. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004;58:193-9.
24. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003;63:1975-80.
25. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 2003;63:1981-9.
26. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
27. Ikonen T, Palvimo JJ, Janne OA. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem. 1997;272:29821-8.
28. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Janne OA. Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem. 1996;271:24151-6.
29. Kasper S, Rennie PS, Bruchovsky N, Sheppard PC, Cheng H, Lin L, Shiu RP, Snoek R, Matusik RJ. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem. 1994;269:31763-9.
30. Morris JD, Pramanik R, Zhang X, Carey AM, Ragavan N, Martin FL, Muir GH. Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cancer Lett 2006;239:111-22.
31. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F. Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19:5406-17.
32. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999;18:6322-9.
33. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002;197:231-8.
34. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/ Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999;96:5458-63.
35. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. 2: Tumorigenic cell lines. Prostate 1997;30:58-64.
36. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Uberall F, Klocker H. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 1999;59:227-33.
37. Gioeli D, Zecevic M, Weber MJ. Immunostaining for activated extracellular signal-regulated kinases in cells and tissues. Methods Enzymol 2001;332:343-53.
38. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-19.
39. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002;277: 29304-14.
40. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002;277:38087-94.
41. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002;62:5632-6.
42. Rowan BG, Weigel NL, O'Malley BW. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem 2000;275:4475-83.
43. Franco OE, Onishi T, Yamakawa K, Arima K, Yanagawa M, Sugimura Y, Kawamura J. Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 2003;56:319-25.
44. Chen CD, Sawyers CL. NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22:2862-70.
45. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LW. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 2000; 275:40846-55.